William James Skalecki, | |
120 N Main St Ste 110, West Bend, WI 53095-3353 | |
(262) 707-3052 | |
Not Available |
Full Name | William James Skalecki |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 120 N Main St Ste 110, West Bend, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013662709 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | (* (Not Available)) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
William James Skalecki, W69n463 Foxpointe Ave, Cedarburg, WI 53012-2231 Ph: (262) 707-3052 | William James Skalecki, 120 N Main St Ste 110, West Bend, WI 53095-3353 Ph: (262) 707-3052 |
News Archive
Merz Pharma Group announced today that the subsequent offering period of the tender offer by Merz GmbH & Co. KGaA ("Merz") and its acquisition subsidiary to purchase all of the outstanding shares of common stock of BioForm Medical, Inc. at a price of $5.45 per share, net to the seller in cash (without interest thereon and less any required withholding tax) expired as scheduled at 12:00 midnight, Eastern Standard Time, on February 18, 2010.
Whether fruit, meat or cheese - the quality of food is not always as consumers would like it to be. But, in future, a spectrometer will allow them to gage the quality of food before they buy it. No bigger than a sugar cube, the device is inexpensive to manufacture and could one day even be installed in smartphones.
D2 Pharma Consulting LLC (D2) is a best-in-class national consulting company that works with pharmaceutical and biotech manufacturers on the implementation of REMS compliant distribution programs, in addition to other commercialization activities. D2 structures REMS distribution programs on behalf of their clients that leverage supply chain efficiencies while complying with FDA mandates.
Protecting patients from exposure to poor quality compounded drugs is a fundamental part of the U.S. Food and Drug Administration's drug compounding program, and we are committed to protecting patients.
Anxiety and depression are significantly heightened during times of great stress such as the COVID-19 pandemic.
› Verified 7 days ago